Hepatic Abscess

A hepatic abscess is a localized, encapsulated collection of pus within the liver parenchyma, resulting from an infectious or inflammatory process. It represents a severe, potentially life-threatening condition in dogs and cats, characterized by necrosis, liquefaction, and accumulation of neutrophils, cellular debris, and infectious agents. Hepatic abscesses can be solitary or multiple, and may arise from hematogenous spread, ascending biliary infection, direct extension from adjacent organs, or traumatic inoculation. The clinical spectrum ranges from subclinical to fulminant sepsis, with significant morbidity and mortality if untreated. In veterinary medicine, hepatic abscesses are relatively uncommon but carry a guarded prognosis, especially when associated with systemic involvement or underlying hepatobiliary disease.

The most common bacterial isolates from hepatic abscesses in dogs and cats include Escherichia coli, Staphylococcus spp., Streptococcus spp., Enterococcus spp., Klebsiella pneumoniae, Pseudomonas aeruginosa, and anaerobic organisms such as Bacteroides fragilis, Fusobacterium necrophorum, and Clostridium spp. In cats, Pasteurella multocida and Actinomyces spp. are also reported. Fungal etiologies, though rare, include Candida spp., Aspergillus spp., and Histoplasma capsulatum. Parasitic causes, such as migrating larval stages of Toxocara canis or trematodes (e.g., Platynosomum fastosum in cats), can predispose to abscess formation. Hematogenous spread from bacteremia (e.g., from endocarditis, pyelonephritis, or dental disease) is a common route. Ascending infection from the biliary tract, secondary to cholangitis or cholecystitis, is another important mechanism. Direct extension from peritonitis, pancreatitis, or penetrating wounds can also occur. Immunosuppression, whether from concurrent disease (e.g., diabetes mellitus, hyperadrenocorticism) or iatrogenic (e.g., corticosteroid therapy), increases susceptibility.

Hepatic abscesses are uncommon in companion animals, with no strong breed or sex predilection reported. They can occur at any age, but middle-aged to older animals are more frequently affected, likely due to increased comorbidities. In dogs, large-breed dogs may be overrepresented in cases secondary to hematogenous spread from discospondylitis or endocarditis. In cats, hepatic abscesses are often associated with cholangitis, particularly in cats with concurrent inflammatory bowel disease or pancreatitis (triaditis). Geographic variation exists for specific etiologies, such as histoplasmosis in the Ohio River Valley or trematode infections in tropical regions. No clear seasonal pattern is documented, but trauma-related abscesses may be more common in warmer months when outdoor activity increases.

The pathogenesis of hepatic abscess formation involves a complex interplay between microbial virulence factors and host immune responses. Bacteria gain access to the liver via the portal vein, hepatic artery, or biliary tree. Once in the hepatic parenchyma, they multiply and trigger an acute inflammatory response, characterized by neutrophil infiltration and release of pro-inflammatory cytokines (TNF-α, IL-1, IL-6). This leads to local tissue necrosis and liquefaction, forming an abscess cavity. The host attempts to wall off the infection with a fibrin layer and fibrous capsule, but this can also impede antibiotic penetration. Anaerobic bacteria, often in synergy with aerobes, produce enzymes that enhance tissue destruction and abscess formation. If the abscess ruptures, it can cause peritonitis, septicemia, and disseminated intravascular coagulation (DIC). Chronic abscesses may lead to hepatic fibrosis, portal hypertension, and secondary hepatic dysfunction.

Predisposing factors include any condition that compromises the hepatic immune defense or promotes bacterial seeding. These include: (1) Immunosuppressive diseases (e.g., feline leukemia virus, feline immunodeficiency virus, canine parvovirus, diabetes mellitus, hyperadrenocorticism) or immunosuppressive drugs (corticosteroids, chemotherapy). (2) Hepatobiliary disease, such as cholangitis, cholecystitis, or biliary obstruction, which facilitates ascending infection. (3) Systemic bacteremia from distant foci (e.g., endocarditis, pyometra, prostatitis, dental abscess). (4) Trauma or penetrating wounds to the liver. (5) Foreign body migration (e.g., grass awns). (6) Hepatic neoplasia, which can create necrotic areas prone to secondary infection. (7) Portosystemic shunts, which alter hepatic blood flow and immune surveillance. (8) In cats, triaditis (concurrent cholangitis, pancreatitis, and inflammatory bowel disease) is a significant risk factor.

Clinical signs are often nonspecific and may include fever, lethargy, anorexia, vomiting, diarrhea, weight loss, and abdominal pain. Hepatomegaly may be palpable on abdominal examination. In peracute cases, signs of septic shock (tachycardia, tachypnea, pale mucous membranes, prolonged capillary refill time, hypothermia or hyperthermia) can dominate. Chronic cases may present with intermittent fever, jaundice, and signs of hepatic insufficiency (e.g., hepatic encephalopathy). In cats, clinical signs may be subtle, with lethargy and anorexia being the most common. Some animals may be asymptomatic, with abscesses discovered incidentally on imaging or necropsy.

Differential diagnoses include: (1) Hepatic neoplasia (e.g., hepatocellular carcinoma, metastatic disease, lymphoma) – distinguished by imaging (CT/MRI), cytology, and histopathology; neoplasia often lacks fever and septic signs. (2) Cholangiohepatitis – inflammatory liver disease, often with elevated liver enzymes and bile duct thickening on ultrasound; diagnosis via liver biopsy. (3) Gallbladder mucocele – may cause similar clinical signs and biliary obstruction; ultrasound shows characteristic immobile bile. (4) Pancreatitis – can cause abdominal pain and elevated liver enzymes; diagnosed with pancreatic lipase (cPLI/fPLI) and imaging. (5) Peritonitis – may be primary or secondary to abscess rupture; abdominocentesis and fluid analysis differentiate. (6) Nodular hyperplasia – benign liver nodules, usually asymptomatic; biopsy confirms. (7) Hepatic cyst – fluid-filled, non-infectious; ultrasound and cytology differentiate. (8) Granulomatous hepatitis (e.g., fungal, mycobacterial) – chronic inflammation with granulomas; histopathology and special stains. (9) Liver lobe torsion – rare, but can cause acute abdominal pain and elevated liver enzymes; imaging and surgery. (10) Foreign body migration – may cause hepatic abscess; imaging and exploratory surgery.

The diagnostic approach begins with a thorough history and physical examination. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis. If hepatic abscess is suspected, abdominal ultrasound is the next step, as it is highly sensitive for detecting focal liver lesions. Ultrasound-guided fine-needle aspiration (FNA) of the abscess for cytology and aerobic/anaerobic culture is crucial for definitive diagnosis and antimicrobial selection. If ultrasound is inconclusive or if surgical intervention is planned, computed tomography (CT) may provide better characterization of the abscess and surrounding structures. In cases of suspected sepsis, blood cultures should be obtained. Additional tests may include coagulation profile (to assess for DIC), bile acid testing (if hepatic dysfunction is suspected), and serology/PCR for specific infectious agents (e.g., fungal, parasitic). In stable patients, a liver biopsy may be considered to rule out underlying neoplasia or inflammatory disease.

Hematology often reveals leukocytosis with a left shift (neutrophilia with band neutrophils) and toxic changes in neutrophils. In chronic or severe cases, leukopenia may occur due to sepsis. Anemia may be present due to chronic inflammation or blood loss. Serum biochemistry typically shows elevated liver enzymes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyltransferase (GGT). Hyperbilirubinemia may be present if biliary obstruction or severe hepatic dysfunction occurs. Hypoalbuminemia and hypoglycemia can occur in severe cases. Electrolyte imbalances (e.g., hyponatremia, hypokalemia) may reflect vomiting or sepsis. Coagulation abnormalities (prolonged PT/aPTT, thrombocytopenia) may indicate DIC. Urinalysis may show bilirubinuria, and in cases of concurrent urinary tract infection, bacteriuria. Blood gas analysis may reveal metabolic acidosis. Specific biomarkers such as C-reactive protein (CRP) may be elevated. In cats, feline pancreatic lipase immunoreactivity (fPLI) may be elevated if concurrent pancreatitis.

Radiography: Abdominal radiographs may show hepatomegaly, loss of abdominal detail, or a soft tissue mass in the liver region. Gas within the abscess may appear as a radiolucent area. Thoracic radiographs are indicated to rule out metastatic disease or concurrent pneumonia. Ultrasonography: Hepatic abscesses appear as focal, hypoechoic to anechoic lesions with irregular margins, often with internal echogenic debris or gas shadowing. Doppler ultrasound may show increased vascularity around the abscess. Ultrasound is also useful for guiding FNA and assessing the biliary system for obstruction. Computed Tomography (CT): CT provides superior contrast resolution and can identify multiple abscesses, gas formation, and extrahepatic extension. Contrast-enhanced CT may show rim enhancement. Magnetic Resonance Imaging (MRI): MRI is less commonly used but can provide detailed soft tissue characterization. Endoscopy: Not directly useful for hepatic abscesses, but ERCP (endoscopic retrograde cholangiopancreatography) may be considered for biliary disease. Fluoroscopy: May be used for interventional procedures such as percutaneous drainage.

Cytology of FNA material typically reveals a purulent exudate with degenerate neutrophils, necrotic debris, and variable numbers of bacteria (intracellular and extracellular). Gram staining can help identify bacterial morphology. Aerobic and anaerobic cultures should be performed. Histopathology of liver biopsy (if obtained) shows areas of coagulative necrosis surrounded by a dense inflammatory infiltrate composed of neutrophils, macrophages, and lymphocytes, with fibrosis in chronic cases. Special stains (Gram, Gomori methenamine silver, periodic acid-Schiff) can identify bacteria and fungi. In cases of fungal abscess, fungal hyphae or yeast may be seen.

Treatment involves a multimodal approach: (1) Emergency stabilization: If septic shock is present, aggressive fluid resuscitation with isotonic crystalloids (e.g., Lactated Ringer's solution at 20-30 mL/kg bolus in dogs, 10-20 mL/kg in cats, repeated as needed) and vasopressors (e.g., norepinephrine CRI at 0.05-0.5 mcg/kg/min) may be required. (2) Antimicrobial therapy: Broad-spectrum antibiotics should be initiated immediately after cultures are obtained. A combination of a beta-lactam (e.g., ampicillin 22 mg/kg IV q8h) and an aminoglycoside (e.g., gentamicin 6-8 mg/kg IV q24h in dogs, with careful monitoring) or a fluoroquinolone (e.g., enrofloxacin 5-10 mg/kg IV/PO q24h) plus metronidazole (10-15 mg/kg IV/PO q12h) is often used. Alternatively, amoxicillin-clavulanate (12.5-25 mg/kg PO q12h) or a third-generation cephalosporin (e.g., cefotaxime 25-50 mg/kg IV q8h) can be used. Antibiotic therapy should be adjusted based on culture and sensitivity results and continued for at least 4-6 weeks. (3) Surgical intervention: Ultrasound-guided percutaneous drainage or surgical drainage (marsupialization or partial hepatectomy) may be necessary for large or unresponsive abscesses. Surgical resection is indicated if the abscess is solitary and accessible. (4) Supportive care: Analgesia (e.g., opioids such as buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h), antiemetics (e.g., maropitant 1 mg/kg SC q24h), and nutritional support (e.g., feeding tube if anorexic). Hepatoprotectants such as S-adenosylmethionine (SAMe) 20 mg/kg PO q24h and ursodeoxycholic acid 10-15 mg/kg PO q24h may be beneficial. (5) Management of underlying conditions: Treat concurrent diseases such as diabetes mellitus or hyperadrenocorticism.

The prognosis for hepatic abscess is guarded to poor, especially if there is rupture, sepsis, or underlying immunosuppression. Reported mortality rates in dogs and cats range from 30% to 50%. Negative prognostic indicators include: presence of septic peritonitis, multiple abscesses, anaerobic infection, delayed diagnosis, and failure to respond to initial therapy. With early aggressive treatment, including surgical drainage and appropriate antibiotics, some animals can recover fully. However, recurrence is possible, particularly if the underlying cause is not addressed. Long-term survival is more likely in animals with solitary abscesses and no systemic complications.

Follow-up should include serial clinical examinations and laboratory monitoring. Recheck CBC and serum biochemistry every 1-2 weeks initially, then monthly until resolution. Repeat abdominal ultrasound at 2-4 weeks to assess abscess resolution. If a percutaneous drain was placed, monitor drain output and culture if infection persists. Adjust antibiotic therapy based on culture results and clinical response. Continue antibiotics for at least 4-6 weeks after clinical resolution. Monitor for complications such as biliary obstruction, peritonitis, or hepatic insufficiency. Long-term, periodic liver enzyme monitoring is recommended, especially if underlying hepatobiliary disease is present.

Pearls: (1) Always obtain aerobic and anaerobic cultures from the abscess, as anaerobes are common. (2) Consider hepatic abscess in any febrile patient with elevated liver enzymes and abdominal pain. (3) Ultrasound-guided drainage can be both diagnostic and therapeutic. (4) In cats, always evaluate for concurrent pancreatitis and inflammatory bowel disease. (5) Early surgical consultation is crucial for large or ruptured abscesses. Pitfalls: (1) Delaying antibiotics until after cultures are obtained is acceptable, but do not delay treatment in septic patients. (2) Avoid using aminoglycosides in dehydrated or renally impaired patients. (3) Do not rely solely on medical therapy for large abscesses; drainage is often necessary. (4) Failure to address underlying immunosuppression can lead to recurrence. (5) Do not forget to monitor for DIC in septic patients.

Antimicrobials: (1) Ampicillin: 22 mg/kg IV q8h (dogs and cats). (2) Amoxicillin-clavulanate: 12.5-25 mg/kg PO q12h (dogs and cats). (3) Enrofloxacin: 5-10 mg/kg IV/PO q24h (dogs); 5 mg/kg PO q24h (cats, with caution due to ocular toxicity). (4) Metronidazole: 10-15 mg/kg IV/PO q12h (dogs and cats). (5) Cefotaxime: 25-50 mg/kg IV q8h (dogs and cats). (6) Gentamicin: 6-8 mg/kg IV q24h (dogs); 5-6 mg/kg IV q24h (cats) – monitor renal function. Analgesics: (1) Buprenorphine: 0.01-0.02 mg/kg IV/IM q8-12h. (2) Fentanyl CRI: 2-5 mcg/kg/hr IV. Antiemetics: (1) Maropitant: 1 mg/kg SC q24h (dogs and cats). (2) Ondansetron: 0.1-0.2 mg/kg IV q8-12h. Hepatoprotectants: (1) SAMe: 20 mg/kg PO q24h. (2) Ursodeoxycholic acid: 10-15 mg/kg PO q24h. Fluid therapy: Isotonic crystalloids (LRS or Normosol-R) at maintenance (60-80 mL/kg/day in dogs, 40-60 mL/kg/day in cats) plus deficits. Vasopressors: Norepinephrine CRI at 0.05-0.5 mcg/kg/min if hypotensive despite fluids. All dosages should be adjusted based on renal/hepatic function and clinical response.

Evidence-based literature on hepatic abscesses in veterinary medicine is limited to case series and retrospective studies. A retrospective study of 20 dogs with hepatic abscesses reported that common clinical signs were fever, lethargy, and vomiting; E. coli and Streptococcus spp. were the most frequent isolates; and surgical drainage combined with antibiotics resulted in a 70% survival rate. Another study in cats found an association with cholangitis and pancreatitis, and recommended aggressive surgical and medical management. Consensus guidelines from ACVIM and ECVIM emphasize the importance of early diagnosis, appropriate antimicrobial selection based on culture, and consideration of surgical intervention. There are no prospective randomized controlled trials, but expert opinion supports the use of broad-spectrum antibiotics and drainage. Further research is needed to establish optimal treatment protocols and prognostic factors.